- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc stock price live, this page displays NASDAQ TBPH stock exchange data. View the TBPH premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Theravance Biopharma Inc real time stock price chart below.
What Is the Theravance Biopharma Inc Stock Price Today?
The Theravance Biopharma Inc stock price today is 16.63.
What Is the Stock Symbol for Theravance Biopharma Inc?
The stock ticker symbol for Theravance Biopharma Inc is TBPH.
Is TBPH the Same as $TBPH?
$TBPH is a common way to refer to the Theravance Biopharma Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Theravance Biopharma Inc Trade On?
Theravance Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Theravance Biopharma Inc a Good Stock to Buy?
Determining whether Theravance Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Theravance Biopharma Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TBPH quote. (ISIN: KYG8807B1068)
What Is the Theravance Biopharma Inc Stock Price Today?
The Theravance Biopharma Inc stock price today is 16.63.
What Is the Stock Symbol for Theravance Biopharma Inc?
The stock ticker symbol for Theravance Biopharma Inc is TBPH.
Is TBPH the Same as $TBPH?
$TBPH is a common way to refer to the Theravance Biopharma Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Theravance Biopharma Inc Trade On?
Theravance Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Theravance Biopharma Inc a Good Stock to Buy?
Determining whether Theravance Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Theravance Biopharma Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TBPH quote. (ISIN: KYG8807B1068)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.40
16.81
52 wk Range
8.33
21.03
TBPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.4016.81
52 wk Range
8.3321.03
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TBPH Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
17.20
Upside
+3.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Form DEF 14A Theravance Biopharma Inc For: 3 April
- Investing.com
- Form DEF 14A Theravance Biopharma Inc For: 3 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma Inc Earnings Call Summary for Q3/2025
- Theravance Biopharma reported Q3 2025 EPS of $0.07, surpassing forecasted loss of $0.13, with collaboration revenue up 19% to $20 million, driving a 2.24% stock price increase.
- The company maintained strong financial position with $333 million in cash, no debt, and UPELRI net sales growth of 15% year-over-year to $71.4 million.
- Operating expenses were contained at $22 million (excluding share-based compensation), contributing to the 153.85% positive earnings surprise.
- Management expects $75 million in milestone payments in Q4 2025 and is preparing for potential NDA submission for ampraloxetine.
- CEO Rick Winningham expressed confidence about the upcoming Cypress trial data readout in Q1 2026, which has 'transformational potential' for the company.
Last Updated: 11/10/2025, 05:53 PM
Read Full TranscriptCompare TBPH to Peers and Sector
Metrics to compare | TBPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTBPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.1x | −5.8x | −0.5x | |
PEG Ratio | 0.03 | 1.24 | 0.00 | |
Price / Book | 2.9x | 1.9x | 2.6x | |
Price / LTM Sales | 8.0x | 2.0x | 3.2x | |
Upside (Analyst Target) | 2.4% | 65.0% | 47.6% | |
Fair Value Upside | Unlock | 12.5% | 6.1% | Unlock |
Analyst Ratings
3 Buy
3 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 17.20
(+3.43% Upside)
Earnings
Latest Release
Mar 19, 2026
EPS / Forecast
1.15 / 1.00
Revenue / Forecast
45.89M / 49.75M
People Also Watch
FAQ
What Is the Theravance Biopharma (TBPH) Stock Price Today?
The Theravance Biopharma stock price today is 16.63 USD.
What Stock Exchange Does Theravance Biopharma Trade On?
Theravance Biopharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Theravance Biopharma?
The stock symbol for Theravance Biopharma is "TBPH."
What Is the Theravance Biopharma Market Cap?
As of today, Theravance Biopharma market cap is 853.75M USD.
What Is Theravance Biopharma's Earnings Per Share (TTM)?
The Theravance Biopharma EPS (TTM) is 2.06.
When Is the Next Theravance Biopharma Earnings Date?
Theravance Biopharma will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is TBPH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Theravance Biopharma Stock Split?
Theravance Biopharma has split 0 times.
How Many Employees Does Theravance Biopharma Have?
Theravance Biopharma has 90 employees.
What is the current trading status of Theravance Biopharma (TBPH)?
As of Apr 15, 2026, Theravance Biopharma (TBPH) is trading at a price of 16.63 USD, with a previous close of 16.60 USD. The stock has fluctuated within a day range of 16.40 USD to 16.81 USD, while its 52-week range spans from 8.33 USD to 21.03 USD.
What Is Theravance Biopharma (TBPH) Price Target According to Analysts?
The average 12-month price target for Theravance Biopharma is 17.20 USD, with a high estimate of 21 USD and a low estimate of 15 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +3.43% Upside potential.
What Is the TBPH Premarket Price?
TBPH's last pre-market stock price is 16.74 USD. The pre-market share volume is 220.00, and the stock has decreased by 0.14, or 0.84%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.